Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium.
We evaluated the impact of high dose of zoledronic acid on the superficial vascular network parameters of a membranous bone site. During a 5-day follow-up, significant reduction of the vascular density is observed only in the treated group.


BACKGROUND
The superficial vascularization is of great importance in membranous bone-healing process. A new rat calvarium intravital model was developed to study the short-term effect of a single high dose of zoledronic acid infusion on the superficial vascularization.


METHODS
Optical bone chambers were implanted in the bone tissue surface of Sprague-Dawley rats' calvarium. Nine rats were injected i.v. with 400 µg/kg of zoledronic acid (Z group), and nine rats were injected with vehicle (PSS group). A 5-day follow-up of the vascular network was made by the use of pictures analysis method.


RESULTS
The vascular density significantly decreases only in Z group but there was no significant difference between groups at individual time points. The total length of the vascular network decreases significantly in Z group only (p=0.003) with a significant higher decrease at D3 (p=0.04) and D5 (p=0.02) compared with control. The vascular density related to the smaller vessels (width, 5-10 µm) decreases significantly between T0 and D5 in Z group only (p=0.002).


CONCLUSIONS
With the help of an original intravital animal model a significant modifications on the total length of the vascular network and the vascular density of small vessels are highlighted on a membranous bone site.
Vieillard
M H
MH
Department of Rheumatology, Hôpital Roger Salengro, University Lille Nord de France, CHRU Lille, 59037, Lille cedex, France. mh-vieillard@chru-lille.fr
Paccou
J
J
Cortet
B
B
Biver
E
E
Salleron
J
J
Falgayrac
G
G
Penel
G
G
D000818:Animals; D001808:Blood Vessels / Q000033:anatomy & histology / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D015194:Diffusion Chambers, Culture; D004164:Diphosphonates / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D007091:Image Processing, Computer-Assisted / Q000379:methods; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012886:Skull / Q000098:blood supply* / Q000187:drug effects / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid